Michael Carrell is a seasoned professional in biopharmaceutical manufacturing and technical operations, currently serving as Senior Director, CMC at Salubris Biotherapeutics since June 2023. Prior experience includes leadership roles at Sensei Bio as Director, Antibody CMC, overseeing a technical operations team in the development of monoclonal antibodies, and at REGENXBIO Inc. as Associate Director, Technology Transfer, facilitating the advancement of gene therapies to market. Michael's background also features key positions at Novavax, Teva Biopharmaceuticals USA, and Diosynth-RTP, where experience ranged from project management to upstream manufacturing, consistently driving process optimization and ensuring compliance in cGMP environments. Educational qualifications include a Bachelor’s degree in Biology from Elon University and an MBA in Strategic Business Management from Strayer University.
This person is not in any teams
This person is not in any offices